)
MediWound (MDWD) investor relations material
MediWound Oppenheimer 36th Annual Healthcare Life Sciences Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company overview and product portfolio
Operates as a late-stage biologic company with an FDA-approved, profitable drug and a Phase III asset targeting a multi-billion dollar market.
NexoBrid is approved in over 40 countries, commercialized in the US, Europe, and Japan, and removes burn eschar rapidly without surgery.
EscharEx, in Phase III for chronic wounds, targets a $2.5 billion US market and is supported by global partnerships and recent manufacturing expansion.
Proprietary enzymatic biologic platform uses proteolytic enzymes from pineapple stem for selective tissue removal.
Technology validated in 14 clinical trials and recognized by regulatory agencies.
Clinical and commercial progress
NexoBrid enables rapid burn eschar removal in over 90% of patients, reducing hospital stays and costs, and is used without the need for surgery or anesthesia.
EscharEx uses the same active ingredient as NexoBrid at half concentration, aiming for chronic wound indications like venous leg ulcers and diabetic foot ulcers.
US government provided $140 million in non-dilutive funding, recognizing NexoBrid’s value for mass casualty and battlefield use.
EscharEx Phase III interim readout expected by year-end 2026, with potential label expansion into additional chronic wound indications.
NexoBrid manufacturing facility expansion expected to resolve supply constraints by mid-2026, supporting global demand.
Financial position and growth outlook
Holds $54 million in cash, no debt, and benefits from significant US government collaboration funding.
Facility expansion to be completed in 2026, driving NexoBrid revenue growth through increased capacity and geographic reach.
EscharEx could generate initial revenue as early as 2028, pending successful Phase III results and regulatory progress.
BARDA contract expected to conclude in Q1 2026, supporting stockpiling and new indications for NexoBrid.
No near-term financing pressure due to strong balance sheet and government support.
Next MediWound earnings date
Next MediWound earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage